U.S. markets closed

Eli Lilly and Company (LLY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
224.09-9.45 (-4.05%)
At close: 4:02PM EDT

Eli Lilly and Company

Lilly Corporate Center
Indianapolis, IN 46285
United States
317 276 2000
http://www.lilly.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full Time Employees34,690

Key Executives

NameTitlePayExercisedYear Born
Mr. David A. RicksChairman, CEO & Pres4.24MN/A1968
Dr. Daniel M. SkovronskySr. VP, Chief Scientific Officer & Pres of Lilly Research Labs2.14MN/A1974
Ms. Anat Hakim J.D.Sr. VP, Gen. Counsel & Sec.1.72MN/A1969
Mr. Alfonso G. ZuluetaSr. VP & Pres of Lilly International1.85MN/A1963
Mr. Joshua L. SmileyExec. Officer1.04MN/A1970
Ms. Anat AshkenaziSr. VP & CFON/AN/A1973
Mr. Donald A. ZakrowskiChief Accounting Officer & VP of Fin.N/AN/AN/A
Mr. Martin Bott MIBSVP of Fin. & Special ProjectsN/AN/A1963
Mr. Diogo RauSr. VP & Chief Information and Digital OfficerN/AN/AN/A
Kevin HernVP of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Corporate Governance

Eli Lilly and Company’s ISS Governance QualityScore as of June 1, 2021 is 8. The pillar scores are Audit: 4; Board: 10; Shareholder Rights: 9; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.